Staging and prognostication of multiple myeloma

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Expert Review of Hematology

• Publication date

  2014-01-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/17474086.2014.882224PMID 24483346PMCID PMC4201368
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Genetic Architecture of Multiple Myeloma

  2014cited by this paper
• Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients

  2013cited by this paper
• Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project

  2013cited by this paper
• Results of a randomized phase III trial of mirabegron in patients with overactive bladder.

  2013cited by this paper
• Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

  2013influential reference
• Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial

  2013cited by this paper
• A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

  2013cited by this paper
• Myeloma: classification and risk assessment.

  2013cited by this paper
• Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma

  2013cited by this paper
• High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.

  2013cited by this paper
• A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma

  2013cited by this paper
• Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease

  2013cited by this paper
• Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach.

  2013cited by this paper
• A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue

  2013cited by this paper
• Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype

  2013cited by this paper
• Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma.

  2012cited by this paper
• High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.

  2012cited by this paper
• Clonal competition with alternating dominance in multiple myeloma.

  2012cited by this paper
• Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites

  2012cited by this paper
• Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

  2012cited by this paper
• Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study.

  2012cited by this paper
• Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.

  2012cited by this paper
• The genetic architecture of multiple myeloma

  2012cited by this paper
• Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

  2012influential reference
• The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.

  2012cited by this paper
• A gene expression signature for high-risk multiple myeloma

  2012cited by this paper
• Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.

  2012influential reference
• Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

  2012influential reference
• Lenalidomide after stem-cell transplantation for multiple myeloma.

  2012cited by this paper
• Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

  2012cited by this paper
• A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

  2012cited by this paper
• Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

  2012influential reference
• Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.

  2011cited by this paper
• Initial genome sequencing and analysis of multiple myeloma

  2011cited by this paper
• Patterns of monoclonal immunoglobulins and serum free light chains are significantly different in black compared to white monoclonal gammopathy of undetermined significance (MGUS) patients

  2011cited by this paper
• Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma

  2011cited by this paper
• Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

  2011cited by this paper
• Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

  2010influential reference
• Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

  2010cited by this paper
• Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

  2010cited by this paper
• Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

  2010influential reference
• Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.

  2010cited by this paper
• Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

  2010cited by this paper
• Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.

  2010cited by this paper
• Prognostic significance of copy-number alterations in multiple myeloma.

  2009cited by this paper
• A monoclonal gammopathy precedes multiple myeloma in most patients.

  2009cited by this paper
• The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.

  2009cited by this paper
• Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial

  2009cited by this paper
• Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

  2009cited by this paper
• Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients

  2009cited by this paper
• Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis

  2009cited by this paper
• International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

  2009cited by this paper
• Myeloid neighborhood in myeloma: Cancer's underbelly?

  2009cited by this paper
• Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

  2009cited by this paper
• International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

  2009influential reference
• Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.

  2009cited by this paper
• Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone.

  2009cited by this paper
• Clinical and biological significance of RAS mutations in multiple myeloma

  2008cited by this paper
• Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma.

  2008cited by this paper
• Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.

  2008cited by this paper
• The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition.

  2008cited by this paper
• Multiple myeloma: diagnosis and treatment.

  2008cited by this paper
• Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

  2008cited by this paper
• Genetic aberrations and survival in plasma cell leukemia

  2008cited by this paper
• Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.

  2008influential reference
• VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

  2008influential reference
• Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

  2008cited by this paper
• An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.

  2008cited by this paper
• Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors

  2008cited by this paper
• A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.

  2008cited by this paper
• Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

  2007cited by this paper
• Hyperdiploidy Is a Common Finding in Monoclonal Gammopathy of Undetermined Significance and Monosomy 13 Is Restricted to These Hyperdiploid Patients

  2007cited by this paper
• Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling

  2007cited by this paper
• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only.

  2007cited by this paper
• Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana.

  2007cited by this paper
• Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

  2007cited by this paper
• Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma

  2007cited by this paper
• A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

  2007cited by this paper
• Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

  2007influential reference
• Clinical significance of TP53 mutation in myeloma

  2007cited by this paper
• Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.

  2007cited by this paper
• Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

  2007cited by this paper
• Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

  2006cited by this paper
• High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.

  2006influential reference
• Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.

  2006cited by this paper
• Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.

  2006cited by this paper
• A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

  2006cited by this paper
• Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

  2006cited by this paper
• International staging system for multiple myeloma.

  2005cited by this paper
• Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple

  2005cited by this paper
• Multiple myeloma: diagnosis and treatment.

  2005cited by this paper
• A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

  2005cited by this paper
• Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.

  2005cited by this paper
• Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.

  2005cited by this paper
• Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

  2005cited by this paper
• Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy.

  2005influential reference
• The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant

  2004influential reference
• p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation.

  2004cited by this paper
• Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later.

  2004cited by this paper
• Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma

  2004cited by this paper

• Hyperdiploid myeloma: The silent majority

  2025cites this paper
• Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imaging

  2024cites this paper
• The role of staging in multiple myeloma

  2023cites this paper
• Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.

  2021cites this paper
• Initial Therapeutic Approaches to Patients with Multiple Myeloma

  2021cites this paper
• Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status

  2021cites this paper
• Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium.

  2020cites this paper
• Myeloma

  2020cites this paper
• Altered Expression of MicroRNAs in the Bone Marrow of Multiple Myeloma Patients and their Relationship to Cytogenetic Aberrations.

  2020cites this paper
• CNV Radar: an improved method for somatic copy number alteration characterization in oncology

  2020cites this paper
• Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations

  2019cites this paper
• Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

  2019cites this paper
• Identification of the xenograft and its ascendant sphere-forming cell line as belonging to EBV-induced lymphoma, and characterization of the status of sphere-forming cells

  2019cites this paper
• Longitudinal patient-reported outcomes in patients with multiple myeloma

  2019cites this paper
• Assessing Multiple Myeloma Risk : Differential Expression Analysis and Modeling

  2019cites this paper
• Pretreatment platelet-lymphocyte ratio versus neutrophil-lymphocyte ratio in the prognosis of multiple myeloma : a single center retrospective study

  2019cites this paper
• Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Therapies

  2018cites this paper
• Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification Effective : February 1 , 2018

  2018cites this paper
• Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Agents and Targeted Therapies

  2018cites this paper
• Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum

  2017cites this paper
• Multiple Myeloma: New Perspectives

  2017cites this paper
• Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification Policy # 00461

  2017cites this paper
• Amyloidosis in colon presenting with rectal bleeding in multipl myeloma: A Case Report

  2017cites this paper
• Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?

  2017cites this paper
• 修订的国际分期系统（R-ISS）在初诊多发性骨髓瘤患者预后判断中的意义

  2017cites this paper
• Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification Effective : March 1 , 2017

  2017cites this paper
• Identification of a novel microRNA, miR-4449, as a potential blood based marker in multiple myeloma

  2017cites this paper
• Amyloıdosıs in Colon Presentıng wıth Rectal Bleedıng in Multıpl Myeloma : A Case Report

  2017cites this paper
• [Management of multiple myeloma in Hungary in 2016].

  2016cites this paper
• Genetic interrogation of circulating multiple myeloma cells at single-cell resolution

  2016cites this paper
• Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling.

  2016cites this paper
• Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells

  2016cites this paper
• Revised International Staging System Applied to Real World Multiple Myeloma Patients.

  2016cites this paper
• Resultados de tres esquemas de tratamiento en pacientes con mieloma múltiple mayores de 65 años

  2016cites this paper
• A myeloma multiplex megközelítése

  2016cites this paper
• A myeloma multiplex megközelítése Magyarországon 2016-ban

  2016cites this paper
• Concomitant multiple myeloma spectrum diagnosis in a central retinal vein occlusion: a case report and review

  2016influential citation
• Towards Stratified Medicine in Plasma Cell Myeloma

  2016influential citation
• microRNA-202激活JNK/SAPK信号通路增强多发性骨髓瘤细胞药物敏感性的研究

  2016cites this paper
• Oligo-based High-resolution aCGH Analysis Enhances Routine Cytogenetic Diagnostics in Haematological Malignancies.

  2015cites this paper
• Szpiczak plazmocytowy wysokiego ryzyka

  2015cites this paper
• Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification

  2015cites this paper
• Clinical characteristics of a group of patients with multiple myeloma who had two different λ light chains by immunofixation electrophoresis: A retrospective study from a single center.

  2015cites this paper
• The comprehensive clinical management of multiple myeloma and related-plasma cell disorders

  2014cites this paper
• The Recent Advances and Future Perspectives of Personalized Medicine

  2014cites this paper
• Molecular Genetics and Gene Therapy Aspects of Phenylalanine Hydroxylase (PAH) Related Hyperphenylalaninemias

  2014cites this paper
• Change in ploidy status from hyperdiploid to near-tetraploid in multiple myeloma associated with bortezomib/lenalidomide resistance.

  2014cites this paper